



AVMI Annual General Meeting (AGM)

30 November- 1 December 2016

The Southern Sun, Newlands, Cape Town, South Africa

Héla Kallel, PhD
Senior scientist
Institut Pasteur de Tunis
www.pasteur.tn

Institut Pasteur de Tunis

Missions

- Biomedical Analysis and Public Health Activities
- Production of therapeutic sera and vaccines
- Research & development
- Training

- Administrative Council (16 members)
- Scientific Council : DG + 8 elected members from IPT
- Enlarged Scientific Council: SC+4 Tunisians from outside IPT+4 internationals

- Medical Ethics Committee
- Communication, valorization and technology transfer
- Committee on Health and Safety
- Training committee
- Bioressources
- Quality

Biomedical Analysis and Public Health activities

- ***18 laboratories + 2 services*** (35 biologists): Cover the quasi-totality of clinical biology tests. IPT is recognized for the **expertise** of some of the laboratories in the specialized medical biology.
- IPT hosts several national (rabies, poliomyelitis, measles, bacteria, other) or international **reference centers** (for the Eastern Mediterranean Region/WHO: for poliomyelitis and measles, HPV)
- IPT is a center for **vaccination** (for the travelers) and a center for **rabies treatment and vaccination** (free).

Eastern Mediterranean Regional Training Centre selected

TDR news item
5 May 2015

The Institut Pasteur de Tunis in Tunis, Tunisia, has been selected to be the Eastern Mediterranean Regional Training Centre supported by TDR. This is the sixth and final centre to be chosen for the TDR network, which is designed to expand and coordinate training courses across multiple countries, leading to improved use of health interventions.

Ethics: Adapting and using the World Health Organization's training on ethics for the Tunisian environment and improving the skills of the Tunis Institutional Review Board.

Good health research practice: Training trainers and researchers with the TDR good clinical practice and good clinical laboratory practice courses, as well as the Good Health Research Practice course.

Implementation research: Beginning implementation research courses using the TDR implementation research toolkit, and working with TDR and others to develop a massive open online course (MOOC) on implementation research focused on infectious diseases of poverty.

➤ **Recently a course was held at IPT from 25-27 May, 2016 about Good Clinical Laboratory Practices**


Research & development

Field of activities

- **Infectious diseases +++** (national health priorities) Leishmaniasis, hydatidosis, tuberculosis, viral hepatitis, rabies, papillomavirus, enteroviruses, avian virus, other veterinary microbial diseases, etc.
- **Scorpion and snake biochemistry/immunology**
- **Congenital immune deficiencies/immune disorders**
- **Genetic susceptibility to metabolic and infectious diseases, cancer**
- **R&D biotechnology and bioprocesses** (rabies, measles, Hepatitis E, veterinary vaccines)
- **Bioinformatics and Mathematical modeling**
- **Entomology**
- **Clinical Epidemiology and Control** (including clinical trials)

Bioproduction activities at IP Tunis

- BCG vaccine (freeze-dried and Concentrated BCG)



- Therapeutic sera:

- Anti-scorpions : *Androctonus australis*, *Buthus occitanus*
- Anti-vipera: *Cerastes cerastes*, *Vipera lebetina*
- Anti-rabies





- Production under GMP
- Seeking for WHO prequalification
- Extra capacity of BCG vaccine, snake and scorpion sera



Annual number of doses used of the different products (national market)

Turnover



Weaknesses

- Lack of flexibility of management
- Constraints related to procurement (no dedicated procurement, long acquisition times). This also affects maintenance
- Recruitment and human resources management: the recruitment process is also inadequate (we do not have the possibility to recruit people with profiles adapted to the production of parenteral biologicals)
- High departure (and switch to private sector)
- Absence of a marketing strategy
- Low visibility

Opportunities

- Few producers (BCG and sera)
- Increased needs in the international market
- International needs for BCG: Iran, South Korea, Turkey (for Immune BCG)
- International needs for therapeutic sera: WHO (for African needs), Ethiopia, Morocco, Turkey
- The manufacturing Process is well controlled
- This area can be a strategic sector for wealth creation and economic and social development in Tunisia

Our strategy

- Engaging a partnership with manufacturers/partners to manufacture the products currently in the portfolio of IPT and possibly others under development
- This can be done through a public-private partnership
- This strategy will allow the promotion and implementation, in Tunisia of bio-production structures needed to produce biotechnology-derived products
- IPT will keep all R & D and patenting activities for vaccines and other bioactive molecules. It will carry out all studies necessary for validation and other evidence of the concept through "translational" research and clinical research (CIC)

Agreements achieved

- Korean CDC to transfer the technology of BCG vaccine production
- Human rabies vaccine (2 agreements signed with foreign companies)
- Therapeutic sera (1 agreement signed with one foreign company)